Ophir Eran 4

What Happened

Ophir Eran, President & CEO and a director of Compugen Ltd. (CGEN), exercised stock options and sold shares on April 24, 2026. The filing reports the exercise/acquisition of 5,000 shares at $0.83 per share (cost $4,146) and an open-market sale of 5,000 shares at a weighted average price of $3.20 per share (gross proceeds $16,001). The same filing also lists a derivative conversion/ disposition of 5,000 shares reported at $0.00. The sale was executed under a Rule 10b5-1 trading plan (see footnote).

Key Details

• Transaction date: 2026-04-24; Form 4 filed: 2026-04-27 (timely).
• Option exercise: 5,000 shares acquired at $0.83 each (total cost $4,146).
• Open-market sale: 5,000 shares sold at a weighted avg. $3.20 (gross proceeds $16,001); prices ranged $3.20–$3.205 (footnote).
• Additional derivative entry: 5,000 shares reported disposed at $0.00 (listed separately in the filing).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Notable footnotes:
  • Transaction was executed under a Rule 10b5-1 trading plan adopted Dec 26, 2025 (F1).
  • Sale price is a weighted average; seller can provide per-price breakdown on request (F2).
  • The option vesting schedule is described (25% vested Dec 31, 2023; remainder vests quarterly) (F3).
• Transaction codes: M = option exercise/conversion; S = sale.

Context

• The CEO exercised options and sold the same number of shares on the same day, which is commonly done to cover exercise costs or diversify holdings; the filing’s 10b5-1 note indicates the sale was pre-planned rather than a discretionary trade.
• Purchases (exercises) can signal insider alignment with the company, while routine sales under 10b5-1 plans are often scheduled and not necessarily a negative signal.
• For additional detail (exact post-transaction holdings or per-trade prices within the reported range), request the full Form 4 or the filer’s breakdown as referenced in the footnotes.